Induction of Insulin producing beta cells Regeneration in vivo
Diabetes has become one of the most widespread metabolic disorders with epidemic dimensions affecting almost 6% of the world’s population. Despite modern treatments, the life expectancy of patients with Type 1 diabetes remains red...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2008-02469
REGENERACION DE CELULAS BETA PRODUCTORAS DE INSULINA
146K€
Cerrado
SAF2008-02469
REGENERACION DE CELULAS BETA PRODUCTORAS DE INSULINA
146K€
Cerrado
SAF2008-00962
ESTUDIO DEL PAPEL DE LOS FACTORES DE CRECIMIENTO SIMILARES A...
455K€
Cerrado
BES-2009-012084
REGENERACION DE CELULAS BETA PRODUCTORAS DE INSULINA
22K€
Cerrado
BCELL-T2D
Role of pancreatic beta cell regeneration in the pathofisiol...
100K€
Cerrado
BES-2009-027064
ESTUDIO DEL PAPEL DE LOS FACTORES DE CRECIMIENTO SIMILARES A...
43K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Diabetes has become one of the most widespread metabolic disorders with epidemic dimensions affecting almost 6% of the world’s population. Despite modern treatments, the life expectancy of patients with Type 1 diabetes remains reduced as compared to healthy subjects. There is therefore a need for alternative therapies. Towards this aim, using the mouse, we recently demonstrated that the in vivo forced expression of a single factor in pancreatic alpha-cells is sufficient to induce a continuous regeneration of alpha-cells and their subsequent conversion into beta-like cells, such converted cells being capable of reversing the consequences of chemically-induced diabetes in vivo (Collombat et al. Cell, 2009).
The PI and his team therefore propose to further decipher the mechanisms involved in this alpha-cell-mediated beta-cell regeneration process and determine whether this approach may be applied to adult animals and whether it would efficiently reverse Type 1 diabetes. Furthermore, a major effort will be made to verify whether our findings could be translated to human. Specifically, we will use a tri-partite approach to address the following issues: (1) Can the in vivo alpha-cell-mediated beta-cell regeneration be induced in adults mice? What would be the genetic determinants involved? (2) Can alpha-cell-mediated beta-cell regeneration reverse diabetes in the NOD Type 1 diabetes mouse model? (3) Can adult human alpha-cells be converted into beta-like cells?
Together, these ambitious objectives will most certainly allow us to gain new insight into the mechanisms defining the identity and the reprogramming capabilities of mouse and human endocrine cells and may thereby open new avenues for the treatment of diabetes. Similarly, the determination of the molecular triggers implicated in the beta-cell regeneration observed in our diabetic mice may lead to exciting new findings, including the identification of drugable targets of importance for human diabetic patients.